Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The study is composed of two phase 2 randomized multi‐center substudies: ‐ PREDATOR‐BR: to investigate the role of daratumumab in the setting of biochemical relapse ‐ PREDATOR‐MRD: to investigate the role of daratumumab in minimal residual disease (MRD) reappearance
Epistemonikos ID: a4bb3efa7a65fd47fd520be480c857ce9c5f934b
First added on: May 21, 2024